Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | PDE2A | O00408 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 5/20 | 0.52 |
| ▸ | CD99 | P14209 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25619498 | 1.00 | ADORA2A (0.53) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL25619503 | 0.90 | DNMT1 (0.56) | ADORA2AADORA3ADORA1RNASELDNMT1 | |
| SCHEMBL25619482 | 0.90 | DNMT1 (0.56) | ADORA2AADORA3ADORA1RNASELDNMT1 | |
| SCHEMBL24220765 | 0.88 | PDE2A (0.69) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL23474182 | 0.88 | PDE2A (0.69) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL23474142 | 0.88 | PDE2A (0.69) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL27120145 | 0.84 | AHCY (0.58) | ADORA2AADORA3ADORA1NT5EADORA2B | |
| SCHEMBL17752044 | 0.84 | ADORA2A (0.60) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL18516034 | 0.82 | ADORA2A (0.77) | ADORA2APDE2AADORA3ADORA1ADRA1A | |
| SCHEMBL15459908 | 0.82 | ADORA2A (0.77) | ADORA2APDE2AADORA3ADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | ADORA2A 238/4885PDE2A 1833/4885ADORA3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.